MIRA-1Restorer of wild-type p53 conformation/cellular function CAS# 72835-26-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 72835-26-8 | SDF | Download SDF |
PubChem ID | 227681 | Appearance | Powder |
Formula | C8H9NO4 | M.Wt | 183.16 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | (2,5-dioxopyrrol-1-yl)methyl propanoate | ||
SMILES | CCC(=O)OCN1C(=O)C=CC1=O | ||
Standard InChIKey | YXEWPGYLMHXLPS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H9NO4/c1-2-8(12)13-5-9-6(10)3-4-7(9)11/h3-4H,2,5H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Restores wild-type conformation, function and DNA binding activity to mutant p53. Induces p53 transcriptional transactivation of p21, MDM2 and PUMA, and promotes tumor cell death by apoptosis in a mutant p53-dependent manner in vitro (IC50 = 10μM). |
MIRA-1 Dilution Calculator
MIRA-1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.4597 mL | 27.2985 mL | 54.5971 mL | 109.1941 mL | 136.4927 mL |
5 mM | 1.0919 mL | 5.4597 mL | 10.9194 mL | 21.8388 mL | 27.2985 mL |
10 mM | 0.546 mL | 2.7299 mL | 5.4597 mL | 10.9194 mL | 13.6493 mL |
50 mM | 0.1092 mL | 0.546 mL | 1.0919 mL | 2.1839 mL | 2.7299 mL |
100 mM | 0.0546 mL | 0.273 mL | 0.546 mL | 1.0919 mL | 1.3649 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Restores wild-type conformation, function and DNA binding activity to mutant p53. Induces p53 transcriptional transactivation of p21, MDM2 and PUMA, and promotes tumor cell death by apoptosis in a mutant p53-dependent manner in vitro (IC50 = 10μM).
- Deoxyartemisinin
Catalog No.:BCN4285
CAS No.:72826-63-2
- Atanine
Catalog No.:BCN3317
CAS No.:7282-19-1
- OSI-930
Catalog No.:BCC1253
CAS No.:728033-96-3
- Panaxydol
Catalog No.:BCN3701
CAS No.:72800-72-7
- Estropipate
Catalog No.:BCC7719
CAS No.:7280-37-7
- Linderalactone
Catalog No.:BCN1251
CAS No.:728-61-0
- ICI 118,551 hydrochloride
Catalog No.:BCC4029
CAS No.:72795-01-8
- Mesulergine hydrochloride
Catalog No.:BCC7139
CAS No.:72786-12-0
- β-Funaltrexamine hydrochloride
Catalog No.:BCC6850
CAS No.:72786-10-8
- Senecivernine
Catalog No.:BCN2135
CAS No.:72755-25-0
- Odorinol
Catalog No.:BCN4284
CAS No.:72755-22-7
- Odorine
Catalog No.:BCN4283
CAS No.:72755-20-5
- 1-Benzyl-5-phenylbarbituric acid
Catalog No.:BCC8461
CAS No.:72846-00-5
- Echitoveniline
Catalog No.:BCN7490
CAS No.:72855-79-9
- Crocandine
Catalog No.:BCN2070
CAS No.:72855-83-5
- Agatharesinol
Catalog No.:BCN4594
CAS No.:7288-11-1
- CHIR-090
Catalog No.:BCC1477
CAS No.:728865-23-4
- Benzoyloxypeoniflorin
Catalog No.:BCN2799
CAS No.:72896-40-3
- 4-Propenylbrenzcatechin
Catalog No.:BCN3672
CAS No.:72898-29-4
- Isocrocandine
Catalog No.:BCN2071
CAS No.:72903-70-9
- O-Methylcedrelopsin
Catalog No.:BCN3637
CAS No.:72916-61-1
- (Z)-Butylidenephthalide
Catalog No.:BCN4007
CAS No.:72917-31-8
- α,β-Methyleneadenosine 5'-triphosphate trisodium salt
Catalog No.:BCC3591
CAS No.:7292-42-4
- (RS)-4-Carboxyphenylglycine
Catalog No.:BCC6601
CAS No.:7292-81-1
Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis.[Pubmed:25617798]
Cancer Lett. 2015 Apr 10;359(2):211-7.
Although numerous studies have focused on the mechanisms of action of the candidate chemotherapeutic drug MIRA-1/NSC19630, initially described as a mutant p53-reactivating small molecule, the issue of its toxicological evaluation remains open. Here, we devised a strategy to examine the effects of MIRA-1 on a variety of human normal cells and cancer cell lines. First, we demonstrated a massive and rapid (within 2 hours) MIRA-1 apoptotic effect on human normal primary epithelial cells as shown using an intestinal mucosa explant assay. MIRA-1 was also cytotoxic to primary and subcultured human mesenchymal cells. Interestingly these effects were restricted to actively proliferating cells. Second, MIRA-1 acute toxicity was independent of p53, since it occurred in human normal cells with increased or silenced p53 expression level, in cancer cells derived from solid or liquid tumors, with either mutated or wt TP53, and in cancer cells devoid of p53. Third, combined pharmacological and genetic approaches showed that MIRA-1 acute cytotoxicity was mediated by a caspase-9-dependent apoptosis. In conclusion, our strategy unveils the limitations of the targeted action of a small molecule designed to reactivate mutant p53.
Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.[Pubmed:17471343]
Trans Am Ophthalmol Soc. 2006;104:221-31.
PURPOSE: To present an initial evaluation of the final data from the Multicenter Investigation of Rheopheresis for age-related macular degeneration (AMD) (MIRA-1) trial. This was a 12-month randomized, prospective, multicenter, double-masked, placebo-controlled, Food and Drug Administration approved clinical trial designed to compare rheopheresis treatment with placebo-control treatment. METHODS: Patients that had nonexudative age-related macular degeneration (AMD) and certain hemorheologic abnormalities were randomized to either rheopheresis or sham treatment in a 2:1 fashion. Best-corrected visual acuity was determined before and at 3, 6, 9, and 12 months following treatment. Adverse events were also recorded. RESULTS: A total of 216 patients were randomized. Of these, 18 were not included in the vision or adverse events evaluation because they did not complete one treatment. This decreased the number of patients that were evaluated for adverse events to 198 patients. In this group, there were 27 serious adverse events, but only 1.8 % of treatments were suspended because of adverse events. At 12 months, there were 104 treated patients and 63 placebo patients that had follow-up. The treated patients had a logMAR vision improvement of 0.02 +/- 0.213, and the placebo patients had a vision improvement of 0.02 +/- 0.20. This was not statistically significant (P = .977). The repeated measure P value for the entire time interval was not significant (P = .69). There appeared to be patients entered into the study that did not meet inclusion criteria. Excluding 37% of the treated patients and 29% of the placebo data from the analysis, there appeared to be statistically significant improvement in the treated patients compared to the control patients at 1 year with a P value of .001 (repeated measures P value = .01). CONCLUSIONS: At best this was a flawed study in that 37% of the treated cases did not meet inclusion criteria, and at worst there was no evidence of effect. Even though the number of serious adverse events is small, because this study did not show an effect in the intent-to-treat group, rheopheresis should not be performed for AMD outside of an approved randomized controlled trial.
Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.[Pubmed:24691427]
Br J Cancer. 2014 Apr 29;110(9):2224-31.
BACKGROUND: Small molecule MIRA-1 induced mutant p53-dependent apoptosis in several types of solid tumours. However, anti-tumour activity of MIRA-1 in haematological malignancies including multiple myeloma (MM) is unknown. In this study, we evaluated the effect of MIRA-1 in MM. METHODS: We examined the anti-tumour activity of MIRA-1 alone or in combination with current anti-myeloma agents in a panel of MM cell lines, primary MM samples, and in a mouse xenograft model of MM. RESULTS: MIRA-1 treatment resulted in the inhibition of viability, colony formation, and migration and increase in apoptosis of MM cells irrespective of p53 status accompanied by upregulation of Puma and Bax and downregulation of Mcl-1 and c-Myc. Genetic knockdown of p53 did not abrogate apoptotic response of MIRA-1. MIRA-1 triggered activation of PERK and IRE-alpha leading to splicing of XBP1 indicating an association of endoplasmic reticulum stress response. Furthermore, combined treatment of MIRA-1 with dexamethasone, doxorubicin or velcade displayed synergistic response in MM cells. Importantly, MIRA-1 alone or in combination with dexamethasone retarded tumour growth and prolonged survival without showing any untoward toxicity in the mice bearing MM tumour. CONCLUSIONS: Our data provide the preclinical framework for clinical evaluation of MIRA-1 as a novel therapeutic agent to improve patient outcome in MM.
p53 in breast cancer: mutation and countermeasures.[Pubmed:17485365]
Front Biosci. 2007 May 1;12:4168-78.
p53 is the primary arbiter of the mammalian cell's response to stress, the governor of life and death. It is the nexus upon which signals converge from an array of sensors that detect damage to DNA or to the mitotic spindle or the cytoskeleton, hypoxia, cell detachment, growth factor deprivation, oncogene expression and other forms of stress. Depending on the type, intensity and duration of the signals, p53 in turn transactivates batteries of genes specifying cell cycle arrest, DNA repair, apoptosis, or other anti-neoplastic functions. At the same time, p53 represses anti-apoptotic and survival functions. The type, intensity and duration of signaling dictate the sequellae. While this response is combinatorial, the frequent perturbation of p53 function in a wide spectrum of cancers attests to its central role in the suppression of neoplasia. As our understanding of regulation by and of p53 has deepened, many possibilities have been suggested for re-establishing p53 or its effectors in tumor cells. This review will briefly summarize the role of p53 mutations in the etiology and treatment of breast cancer and then consider the wide array of strategies being developed to re-establish p53 function in tumor cells.
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.[Pubmed:15998635]
J Biol Chem. 2005 Aug 26;280(34):30384-91.
Reactivation of mutant p53 is likely to provide important benefits for treatment of chemotherapy- and radiotherapy-resistant tumors. We demonstrate here that the maleimide-derived molecule MIRA-1 can reactivate DNA binding and preserve the active conformation of mutant p53 protein in vitro and restore transcriptional transactivation to mutant p53 in living cells. MIRA-1 induced mutant p53-dependent cell death in different human tumor cells carrying tetracycline-regulated mutant p53. The structural analog MIRA-3 showed antitumor activity in vivo against human mutant p53-carrying tumor xenografts in SCID mice. The MIRA scaffold is a novel lead for the development of anticancer drugs specifically targeting mutant p53.